The Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional) call from the National Institutes of Health (NIH) supports implementation research projects in the USA.
Proposals must address strategies to improve the uptake, implementation, sustainment, scale, and spread of evidence-based HIV prevention, treatment, and care interventions in U.S. communities significantly impacted by HIV.
Applications are open to organizations based in the United States. Applications must be grounded in implementation science and meaningfully engage people or communities affected by HIV.
R61 phase budgets are limited to 750,000 USD in direct costs per year, while R33 phase budgets are not capped. The R61 phase may last up to 2 years and the R33 phase up to 4 years, with a maximum total project period of 5 years.
Opportunity number: RFA-AI-27-018
Applications close on November 10, 2026, with additional cycles closing through June 20, 2029.